Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology and obesity, today announced that
preclinical data supporting TERN-501, a highly selective thyroid
hormone receptor beta (THR-β) receptor agonist, in combination with
a GLP-1 receptor agonist for obesity will be highlighted in a
poster presentation at the American Diabetes Association (ADA) 84th
Scientific Sessions, taking place June 21 – 24, 2024 in Orlando,
FL.
“While GLP-1 receptor agonists facilitate weight
loss by suppressing food intake, efficacy may be limited by
metabolic adaptation, a counter regulatory process that lowers
energy expenditure in response to weight loss. THR-β agonism, an
orthogonal mechanism to GLP-1, appears to unlock additional
efficacy of GLP-1 therapies by normalizing energy expenditure
during weight loss, while preserving relative lean mass,” said Emil
Kuriakose, M.D., chief medical officer at Terns. “These exciting
results suggest that TERN-501 may be an ideal combination partner
for injectable and oral GLP-1 agonists for use in obesity and other
metabolic disorders by potentially offering broader metabolic
benefits beyond additional weight loss.”
The poster and viewing detail are listed below:
Presentation Title: |
|
TERN-501 Enhances Weight Loss Efficacy of a GLP-1R Agonist in Obese
Mice via Increased Fat Mass Loss without Additional Loss of
Lean Mass |
Abstract
Number: |
|
760 |
Presentation Date and
Time: |
|
Sunday, June 23, 2024 from 12:30
p.m. – 1:30 p.m. ET |
Session: |
|
Clinical
Therapeutics—Incretin-Based Therapies |
Presenter: |
|
Christopher Jones |
The presentation reports results from a preclinical study in
mice fed a high fat diet for 24 weeks prior to study start. Obese
mice were treated once daily with vehicle, TERN-501, semaglutide,
TERN-501+semaglutide, or tirzepatide for six weeks. The combination
of TERN-501+ semaglutide significantly enhanced weight loss
compared to semaglutide alone. Additionally, the
TERN-501+semaglutide combination showed proportionally greater loss
of fat mass relative to lean mass compared to semaglutide alone,
indicating improved quality of weight loss.
The study also explored metabolic adaptation, a counter
regulatory process that decreases energy expenditure and limits the
magnitude and sustainability of weight loss. Mice treated with
semaglutide and tirzepatide showed significant weight loss that was
associated with decreases in energy expenditure. When TERN-501 was
combined with semaglutide, weight loss-induced lowering of energy
expenditure was prevented and increases in the thermogenesis
marker, UCP-1, were observed in subcutaneous adipose tissue.
TERN-501 has potential to attenuate metabolic adaptation and
normalize energy expenditure, which may enhance the weight loss
efficacy of GLP-1 therapies.
The full poster is available on Terns’ scientific publications
website.
In addition, Terns announced that management will participate in
a fireside chat at the Piper Sandler Virtual Obesity Day on June
26, 2024 at 12:30pm ET. The Piper Sandler event webcast link is
available from Piper Sandler and will require registration.
About TERN-501
TERN-501 is a THR-β agonist with high metabolic stability,
enhanced liver distribution and greater selectivity for THR-β
compared to other THR-β agonists in development. The Phase 2a DUET
trial (NCT05415722) produced positive top-line data in August 2023;
showing compelling MRI-PDFF reductions and best-in-class safety and
tolerability profile with TERN-501 in MASH. Terns has deprioritized
development for MASH given the current regulatory and clinical
development requirements for the indication. Terns continues to
evaluate opportunities for TERN-501, including in other metabolic
diseases, with a focus towards combination regimens for
obesity.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical stage
biopharmaceutical company developing a portfolio of small molecule
product candidates to address serious diseases, including oncology
and obesity. Terns’ pipeline contains three clinical stage
development programs including an allosteric BCR-ABL inhibitor, a
small molecule GLP-1 receptor agonist, a THR-β agonist, and a
preclinical GIPR modulator discovery effort, prioritizing a GIPR
antagonist nomination candidate. For more information, please
visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements about the
Company within the meaning of the federal securities laws,
including those related to expectations, timing and potential
results of the clinical trials and other development activities of
the Company and its partners; the potential indications to be
targeted by the Company with its small molecule product candidates;
the therapeutic potential of the Company’s small molecule product
candidates, including when used in combination with another product
or product candidate; the potential for the mechanisms of action of
the Company’s product candidates to be therapeutic targets for
their targeted indications; the potential utility and progress of
the Company’s product candidates in their targeted indications,
including the clinical utility of the data from and the endpoints
used in the Company’s clinical trials; the Company’s clinical
development plans and activities, the Company’s expectations
regarding the profile of its product candidates, including
efficacy, tolerability, safety, metabolic stability and
pharmacokinetic profile and potential differentiation as compared
to other products or product candidates; and the Company’s plans
for and ability to continue to execute on its current development
strategy, including potential combinations involving multiple
product candidates. All statements other than statements of
historical facts contained in this press release, including
statements regarding the Company’s strategy, future financial
condition, future operations, future trial results, projected
costs, prospects, plans, objectives of management and expected
market growth, are forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as
“aim,” “anticipate,” “assume,” “believe,” “contemplate,”
“continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,”
“intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
“predict,” “seek,” “should,” “target,” “will,” “would” and other
similar expressions that are predictions of or indicate future
events and future trends, or the negative of these terms or other
comparable terminology. The Company has based these forward-looking
statements largely on its current expectations, estimates,
forecasts and projections about future events and financial trends
that it believes may affect its financial condition, results of
operations, business strategy and financial needs. In light of the
significant uncertainties in these forward-looking statements, you
should not rely upon forward-looking statements as predictions of
future events. These statements are subject to risks and
uncertainties that could cause the actual results and the
implementation of the Company’s plans to vary materially, including
the risks associated with the initiation, cost, timing, progress,
results and utility of the Company’s current and future research
and development activities and preclinical studies and clinical
trials. These risks are not exhaustive. For a detailed discussion
of the risk factors that could affect the Company’s actual results,
please refer to the risk factors identified in the Company’s SEC
reports, including but not limited to its Annual Report on Form
10-K for the year ended December 31, 2023. Except as required by
law, the Company undertakes no obligation to update publicly any
forward-looking statements for any reason.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Grafico Azioni Terns Pharmaceuticals (NASDAQ:TERN)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Terns Pharmaceuticals (NASDAQ:TERN)
Storico
Da Nov 2023 a Nov 2024